

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

BioDelivery Sciences International, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 07/23/2020 | Country: USA | Primary Security ID: 09060J106 |
| Record Date: 06/12/2020 | Meeting Type: Annual | Ticker: BDSI |
| Primary CUSIP: 09060J106 | Primary ISIN: US09060J1060 | Primary SEDOL: 2820165 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 1 | Ratification of Declassification and Adoption of Majority Voting for Director Elections | Mgmt | For | For |
| | If Proposal 1 is Approved, Elect Directors 2aa to 2ag | Mgmt | | |
| 2aa | Elect Director Peter S. Greenleaf | Mgmt | For | Against |
| 2ab | Elect Director Todd C. Davis | Mgmt | For | For |
| 2ac | Elect Director Mark A. Sirgo | Mgmt | For | For |
| 2ad | Elect Director Kevin Kotler | Mgmt | For | For |
| 2ae | Elect Director William Mark Watson | Mgmt | For | For |
| 2af | Elect Director Vanila Singh | Mgmt | For | For |
| 2ag | Elect Director Jeffrey Bailey | Mgmt | For | For |
| | If Proposal 1 is Not Approved, Elect Directors 2ba to 2bg | Mgmt | | |
| 2ba | Elect Director Peter S. Greenleaf | Mgmt | For | Against |
| 2bb | Elect Director Todd C. Davis | Mgmt | For | For |
| 2bc | Elect Director Mark A. Sirgo | Mgmt | For | For |
| 2bd | Elect Director Kevin Kotler | Mgmt | For | For |
| 2be | Elect Director William Mark Watson | Mgmt | For | For |
| 2bf | Elect Director Vanila Singh | Mgmt | For | For |
| 2bg | Elect Director Jeffrey Bailey | Mgmt | For | For |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 4 | Increase Authorized Common Stock | Mgmt | For | For |

Jazz Pharmaceuticals plc

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 07/30/2020 | Country: Ireland | Primary Security ID: G50871105 |
| Record Date: 06/03/2020 | Meeting Type: Annual | Ticker: JAZZ |
| Primary CUSIP: G50871105 | Primary ISIN: IE00B4Q5ZN47 | Primary SEDOL: B4Q5ZN4 |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Jazz Pharmaceuticals plc

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Bruce C. Cozadd | Mgmt | For | For |
| 1b | Elect Director Heather Ann McSharry | Mgmt | For | For |
| 1c | Elect Director Anne O'Riordan | Mgmt | For | For |
| 1d | Elect Director Rick E Winningham | Mgmt | For | For |
| 2 | Approve KPMG, Dublin as Auditors and Authorize Board to Fix Their Remuneration | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Amend Non-Employee Director Omnibus Stock Plan | Mgmt | For | Against |
| 5 | Approve Reduction in Capital and Creation of Distributable Reserves | Mgmt | For | For |

Prestige Consumer Healthcare Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 08/04/2020 | Country: USA | Primary Security ID: 74112D101 |
| Record Date: 06/12/2020 | Meeting Type: Annual | Ticker: PBH |
| Primary CUSIP: 74112D101 | Primary ISIN: US74112D1019 | Primary SEDOL: B0650P3 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 1.1 | Elect Director Ronald M. Lombardi | Mgmt | For | For |
| 1.2 | Elect Director John E. Byom | Mgmt | For | For |
| 1.3 | Elect Director Gary E. Costley | Mgmt | For | For |
| 1.4 | Elect Director Christopher J. Coughlin | Mgmt | For | For |
| 1.5 | Elect Director Sheila A. Hopkins | Mgmt | For | For |
| 1.6 | Elect Director James M. Jenness | Mgmt | For | For |
| 1.7 | Elect Director Natale S. Ricciardi | Mgmt | For | For |
| 1.8 | Elect Director Dawn M. Zier | Mgmt | For | For |
| 2 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Prestige Consumer Healthcare Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Approve Omnibus Stock Plan | Mgmt | For | For |

Wave Life Sciences Ltd.

Meeting Date: 08/12/2020

Country: Singapore

Primary Security ID: Y95308105

Record Date: 06/17/2020

Meeting Type: Annual

Ticker: WVE

Primary CUSIP: Y95308105

Primary ISIN: SG9999014716

Primary SEDOL: BYZG9R0

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Paul B. Bolno | Mgmt | For | For |
| 1b | Elect Director Mark H.N. Corrigan | Mgmt | For | For |
| 1c | Elect Director Christian O. Henry | Mgmt | For | For |
| 1d | Elect Director Peter Kolchinsky | Mgmt | For | For |
| 1e | Elect Director Amy Pott | Mgmt | For | For |
| 1f | Elect Director Adrian Rawcliffe | Mgmt | For | For |
| 1g | Elect Director Ken Takanashi | Mgmt | For | Against |
| 1h | Elect Director Aik Na Tan | Mgmt | For | For |
| 1i | Elect Director Gregory L. Verdine | Mgmt | For | For |
| 1j | Elect Director Heidi L. Wagner | Mgmt | For | For |
| 2 | Approve KPMG LLP as Auditors and Authorize Audit Committee to Fix Their Remuneration | Mgmt | For | For |
| 3 | Approve Non-Employee Directors' Compensation | Mgmt | For | For |
| 4 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Mgmt | For | For |
| 5 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Catalent, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 10/29/2020 | Country: USA | Primary Security ID: 148806102 |
| Record Date: 09/02/2020 | Meeting Type: Annual | Ticker: CTLT |
| Primary CUSIP: 148806102 | Primary ISIN: US1488061029 | Primary SEDOL: BP96PQ4 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Madhavan "Madhu" Balachandran | Mgmt | For | For |
| 1b | Elect Director J. Martin Carroll | Mgmt | For | For |
| 1c | Elect Director Rolf Classon | Mgmt | For | For |
| 1d | Elect Director John J. Greisch | Mgmt | For | For |
| 1e | Elect Director Christa Kreuzburg | Mgmt | For | For |
| 1f | Elect Director Gregory T. Lucier | Mgmt | For | Against |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Phibro Animal Health Corporation

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 11/02/2020 | Country: USA | Primary Security ID: 71742Q106 |
| Record Date: 09/03/2020 | Meeting Type: Annual | Ticker: PAHC |
| Primary CUSIP: 71742Q106 | Primary ISIN: US71742Q1067 | Primary SEDOL: BL95N25 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 1.1 | Elect Director Daniel M. Bendheim | Mgmt | For | Withhold |
| 1.2 | Elect Director Jonathan Bendheim | Mgmt | For | Withhold |
| 1.3 | Elect Director Sam Gejdenson | Mgmt | For | Withhold |
| 2 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Johnson & Johnson

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 04/22/2021 | Country: USA | Primary Security ID: 478160104 |
| Record Date: 02/23/2021 | Meeting Type: Annual | Ticker: JNJ |
| Primary CUSIP: 478160104 | Primary ISIN: US4781601046 | Primary SEDOL: 2475833 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 1a | Elect Director Mary C. Beckerle | Mgmt | For | For |
| 1b | Elect Director D. Scott Davis | Mgmt | For | For |
| 1c | Elect Director Ian E. L. Davis | Mgmt | For | For |
| 1d | Elect Director Jennifer A. Doudna | Mgmt | For | For |
| 1e | Elect Director Alex Gorsky | Mgmt | For | For |
| 1f | Elect Director Marillyn A. Hewson | Mgmt | For | For |
| 1g | Elect Director Hubert Joly | Mgmt | For | For |
| 1h | Elect Director Mark B. McClellan | Mgmt | For | For |
| 1i | Elect Director Anne M. Mulcahy | Mgmt | For | Against |
| 1j | Elect Director Charles Prince | Mgmt | For | For |
| 1k | Elect Director A. Eugene Washington | Mgmt | For | For |
| 1l | Elect Director Mark A. Weinberger | Mgmt | For | For |
| 1m | Elect Director Nadja Y. West | Mgmt | For | For |
| 1n | Elect Director Ronald A. Williams | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | Abstain |
| 3 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |
| 4 | Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics | SH | Against | Against |
| 5 | Require Independent Board Chair | SH | Against | Against |
| 6 | Report on Civil Rights Audit | SH | Against | Against |
| 7 | Adopt Policy on Bonus Banking | SH | Against | Against |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Pfizer Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 04/22/2021 | Country: USA | Primary Security ID: 717081103 |
| Record Date: 02/24/2021 | Meeting Type: Annual | Ticker: PFE |
| Primary CUSIP: 717081103 | Primary ISIN: US7170811035 | Primary SEDOL: 2684703 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Ronald E. Blaylock | Mgmt | For | For |
| 1.2 | Elect Director Albert Bourla | Mgmt | For | For |
| 1.3 | Elect Director Susan Desmond-Hellmann | Mgmt | For | For |
| 1.4 | Elect Director Joseph J. Echevarria | Mgmt | For | Against |
| 1.5 | Elect Director Scott Gottlieb | Mgmt | For | For |
| 1.6 | Elect Director Helen H. Hobbs | Mgmt | For | For |
| 1.7 | Elect Director Susan Hockfield | Mgmt | For | For |
| 1.8 | Elect Director Dan R. Littman | Mgmt | For | For |
| 1.9 | Elect Director Shantanu Narayen | Mgmt | For | For |
| 1.10 | Elect Director Suzanne Nora Johnson | Mgmt | For | For |
| 1.11 | Elect Director James Quincey | Mgmt | For | For |
| 1.12 | Elect Director James C. Smith | Mgmt | For | For |
| 2 | Ratify KPMG LLP as Auditor | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Require Independent Board Chair | SH | Against | Against |
| 5 | Report on Political Contributions and Expenditures | SH | Against | Abstain |
| 6 | Report on Access to COVID-19 Products | SH | Against | Against |

Theravance Biopharma, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 04/27/2021 | Country: Cayman Islands | Primary Security ID: G8807B106 |
| Record Date: 03/01/2021 | Meeting Type: Annual | Ticker: TBPH |
| Primary CUSIP: G8807B106 | Primary ISIN: KYG8807B1068 | Primary SEDOL: BMNDK09 |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Theravance Biopharma, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Eran Broshy | Mgmt | For | For |
| 1.2 | Elect Director Laurie Smaldone Alsup | Mgmt | For | For |
| 1.3 | Elect Director Burton G. Malkiel | Mgmt | For | For |
| 2 | Ratify Appointment of Deepika R. Pakianathan as Director | Mgmt | For | Against |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Horizon Therapeutics Public Limited Company

Meeting Date: 04/29/2021 **Country:** Ireland **Primary Security ID:** G46188101
Record Date: 02/24/2021 **Meeting Type:** Annual **Ticker:** HZNP
Primary CUSIP: G46188101 **Primary ISIN:** IE00BQPVQZ61 **Primary SEDOL:** BQPVQZ6

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director William F. Daniel | Mgmt | For | For |
| 1b | Elect Director H. Thomas Watkins | Mgmt | For | For |
| 1c | Elect Director Pascale Witz | Mgmt | For | For |
| 2 | Approve PricewaterhouseCoopers LLP as Auditors and Authorize Board to Fix Their Remuneration | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Authorize Market Purchases or Overseas Market Purchases of Ordinary Shares | Mgmt | For | For |
| 5 | Amend Omnibus Stock Plan | Mgmt | For | For |

Eli Lilly and Company

Meeting Date: 05/03/2021 **Country:** USA **Primary Security ID:** 532457108
Record Date: 02/22/2021 **Meeting Type:** Annual **Ticker:** LLY
Primary CUSIP: 532457108 **Primary ISIN:** US5324571083 **Primary SEDOL:** 2516152

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Eli Lilly and Company

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 1a | Elect Director Katherine Baicker | Mgmt | For | For |
| 1b | Elect Director J. Erik Fyrwald | Mgmt | For | Against |
| 1c | Elect Director Jamere Jackson | Mgmt | For | For |
| 1d | Elect Director Gabrielle Sulzberger | Mgmt | For | For |
| 1e | Elect Director Jackson P. Tai | Mgmt | For | Against |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 4 | Declassify the Board of Directors | Mgmt | For | For |
| 5 | Eliminate Supermajority Vote Requirement | Mgmt | For | For |
| 6 | Report on Lobbying Payments and Policy | SH | Against | For |
| 7 | Require Independent Board Chair | SH | Against | Against |
| 8 | Adopt Policy on Bonus Banking | SH | Against | Against |
| 9 | Clawback Disclosure of Recoupment Activity from Senior Officers | SH | Against | For |

Bristol-Myers Squibb Company

Meeting Date: 05/04/2021

Country: USA

Primary Security ID: 110122108

Record Date: 03/15/2021

Meeting Type: Annual

Ticker: BMY

Primary CUSIP: 110122108

Primary ISIN: US1101221083

Primary SEDOL: 2126335

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|----------------------------------|-----------|----------|------------------|
| 1A | Elect Director Peter J. Arduini | Mgmt | For | For |
| 1B | Elect Director Michael W. Bonney | Mgmt | For | Against |
| 1C | Elect Director Giovanni Caforio | Mgmt | For | For |
| 1D | Elect Director Julia A. Haller | Mgmt | For | For |
| 1E | Elect Director Paula A. Price | Mgmt | For | For |
| 1F | Elect Director Derica W. Rice | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Bristol-Myers Squibb Company

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1G | Elect Director Theodore R. Samuels | Mgmt | For | For |
| 1H | Elect Director Gerald L. Storch | Mgmt | For | For |
| 1I | Elect Director Karen H. Vousden | Mgmt | For | For |
| 1J | Elect Director Phyllis R. Yale | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Approve Omnibus Stock Plan | Mgmt | For | For |
| 4 | Ratify Deloitte & Touche LLP as Auditors | Mgmt | For | For |
| 5 | Reduce Ownership Threshold for Special Shareholder Meetings to 15% | Mgmt | For | For |
| 6 | Require Independent Board Chair | SH | Against | Against |
| 7 | Provide Right to Act by Written Consent | SH | Against | Against |
| 8 | Reduce Ownership Threshold for Special Shareholder Meetings to 10% | SH | Against | Against |

Amneal Pharmaceuticals, Inc.

Meeting Date: 05/05/2021

Country: USA

Primary Security ID: 03168L105

Record Date: 03/12/2021

Meeting Type: Annual

Ticker: AMRX

Primary CUSIP: 03168L105

Primary ISIN: US03168L1052

Primary SEDOL: BFNFD6

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|------------------------------------|-----------|----------|------------------|
| 1a | Elect Director Emily Peterson Alva | Mgmt | For | Against |
| 1b | Elect Director J. Kevin Buchi | Mgmt | For | Against |
| 1c | Elect Director Jeff George | Mgmt | For | For |
| 1d | Elect Director John Kiely | Mgmt | For | Against |
| 1e | Elect Director Paul Meister | Mgmt | For | Against |
| 1f | Elect Director Ted Nark | Mgmt | For | For |
| 1g | Elect Director Chintu Patel | Mgmt | For | For |
| 1h | Elect Director Chirag Patel | Mgmt | For | For |
| 1i | Elect Director Gautam Patel | Mgmt | For | Against |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Amneal Pharmaceuticals, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1j | Elect Director Shlomo Yanai | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Amend Charter to Remove References to Class B-1 Common Stock | Mgmt | For | For |
| 4 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Revance Therapeutics, Inc.

Meeting Date: 05/05/2021 **Country:** USA **Primary Security ID:** 761330109
Record Date: 03/11/2021 **Meeting Type:** Annual **Ticker:** RVNC
Primary CUSIP: 761330109 **Primary ISIN:** US7613301099 **Primary SEDOL:** BJFSR99

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Angus C. Russell | Mgmt | For | Withhold |
| 1.2 | Elect Director Julian S. Gangolli | Mgmt | For | For |
| 1.3 | Elect Director Olivia C. Ware | Mgmt | For | For |
| 2 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Increase Authorized Common Stock | Mgmt | For | For |

Perrigo Company plc

Meeting Date: 05/12/2021 **Country:** Ireland **Primary Security ID:** G97822103
Record Date: 03/15/2021 **Meeting Type:** Annual **Ticker:** PRGO
Primary CUSIP: G97822103 **Primary ISIN:** IE00BGH1M568 **Primary SEDOL:** BGH1M56

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|-----------------------------------|-----------|----------|------------------|
| 1.1 | Elect Director Bradley A. Alford | Mgmt | For | For |
| 1.2 | Elect Director Orlando D. Ashford | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Perrigo Company plc

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 1.3 | Elect Director Rolf A. Classon | Mgmt | For | For |
| 1.4 | Elect Director Katherine C. Doyle | Mgmt | For | For |
| 1.5 | Elect Director Adriana Karaboutis | Mgmt | For | Against |
| 1.6 | Elect Director Murray S. Kessler | Mgmt | For | For |
| 1.7 | Elect Director Jeffrey B. Kindler | Mgmt | For | For |
| 1.8 | Elect Director Erica L. Mann | Mgmt | For | For |
| 1.9 | Elect Director Donal O'Connor | Mgmt | For | For |
| 1.10 | Elect Director Geoffrey M. Parker | Mgmt | For | For |
| 1.11 | Elect Director Theodore R. Samuels | Mgmt | For | For |
| 2 | Approve Ernst & Young LLP as Auditors and Authorize Board to Fix Their Remuneration | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Authorize Issue of Equity | Mgmt | For | For |
| 5 | Authorize Issuance of Equity without Preemptive Rights | Mgmt | For | For |

Provention Bio, Inc.

Meeting Date: 05/12/2021

Country: USA

Primary Security ID: 74374N102

Record Date: 03/15/2021

Meeting Type: Annual

Ticker: PRVB

Primary CUSIP: 74374N102

Primary ISIN: US74374N1028

Primary SEDOL: BG346B3

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|----------------------------------|-----------|----------|------------------|
| 1.1 | Elect Director Ashleigh Palmer | Mgmt | For | For |
| 1.2 | Elect Director Jeffrey Bluestone | Mgmt | For | For |
| 1.3 | Elect Director Avery Catlin | Mgmt | For | For |
| 1.4 | Elect Director Sean Doherty | Mgmt | For | For |
| 1.5 | Elect Director Wayne Pisano | Mgmt | For | For |
| 1.6 | Elect Director Nancy Wysenski | Mgmt | For | For |
| 1.7 | Elect Director John Jenkins | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Provention Bio, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Advisory Vote on Say on Pay Frequency | Mgmt | One Year | One Year |
| 4 | Increase Authorized Common Stock | Mgmt | For | For |
| 5 | Ratify EisnerAmper LLP as Auditors | Mgmt | For | For |

Innoviva, Inc.

Meeting Date: 05/14/2021 **Country:** USA **Primary Security ID:** 45781M101
Record Date: 03/29/2021 **Meeting Type:** Annual **Ticker:** INVA
Primary CUSIP: 45781M101 **Primary ISIN:** US45781M1018 **Primary SEDOL:** BDDXF67

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director George W. Bickerstaff, III | Mgmt | For | For |
| 1b | Elect Director Deborah L. Bix | Mgmt | For | For |
| 1c | Elect Director Mark A. DiPaolo | Mgmt | For | Against |
| 1d | Elect Director Jules Haimovitz | Mgmt | For | For |
| 1e | Elect Director Odysseas D. Kostas | Mgmt | For | Against |
| 1f | Elect Director Sarah J. Schlesinger | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Ratify Grant Thornton LLP as Auditors | Mgmt | For | For |

Elanco Animal Health Incorporated

Meeting Date: 05/19/2021 **Country:** USA **Primary Security ID:** 28414H103
Record Date: 03/15/2021 **Meeting Type:** Annual **Ticker:** ELAN
Primary CUSIP: 28414H103 **Primary ISIN:** US28414H1032 **Primary SEDOL:** BF5L3T2

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Elanco Animal Health Incorporated

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director William F. Doyle | Mgmt | For | Against |
| 1b | Elect Director Art A. Garcia | Mgmt | For | For |
| 1c | Elect Director Denise Scots-Knight | Mgmt | For | For |
| 1d | Elect Director Jeffrey N. Simmons | Mgmt | For | For |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Amend Omnibus Stock Plan | Mgmt | For | For |

Collegium Pharmaceutical, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 05/20/2021 | Country: USA | Primary Security ID: 19459J104 |
| Record Date: 03/31/2021 | Meeting Type: Annual | Ticker: COLL |
| Primary CUSIP: 19459J104 | Primary ISIN: US19459J1043 | Primary SEDOL: BX7RSN3 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Rita Balice-Gordon | Mgmt | For | For |
| 1.2 | Elect Director Garen Bohlin | Mgmt | For | For |
| 1.3 | Elect Director Gwen Melincoff | Mgmt | For | For |
| 1.4 | Elect Director Theodore Schroeder | Mgmt | For | Against |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Ratify Deloitte & Touche LLP as Auditors | Mgmt | For | For |

Relmada Therapeutics, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 05/20/2021 | Country: USA | Primary Security ID: 75955J402 |
| Record Date: 03/22/2021 | Meeting Type: Annual | Ticker: RLMD |
| Primary CUSIP: 75955J402 | Primary ISIN: US75955J4022 | Primary SEDOL: BK71LV3 |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Relmada Therapeutics, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|-------------|------------------|
| 1.1 | Elect Director John Glasspool | Mgmt | For | Withhold |
| 1.2 | Elect Director Paul Kelly | Mgmt | For | For |
| 2 | Ratify Marcum LLP as Auditors | Mgmt | For | For |
| 3 | Approve Omnibus Stock Plan | Mgmt | For | Against |
| 4 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 5 | Advisory Vote on Say on Pay Frequency | Mgmt | Three Years | One Year |

Zoetis Inc.

Meeting Date: 05/20/2021 **Country:** USA **Primary Security ID:** 98978V103
Record Date: 03/26/2021 **Meeting Type:** Annual **Ticker:** ZTS
Primary CUSIP: 98978V103 **Primary ISIN:** US98978V1035 **Primary SEDOL:** B95WG16

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Sanjay Khosla | Mgmt | For | For |
| 1b | Elect Director Antoinette R. Leatherberry | Mgmt | For | For |
| 1c | Elect Director Willie M. Reed | Mgmt | For | For |
| 1d | Elect Director Linda Rhodes | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Ratify KPMG LLP as Auditor | Mgmt | For | For |
| 4 | Adopt Simple Majority Vote | SH | Against | For |

Phathom Pharmaceuticals, Inc.

Meeting Date: 05/21/2021 **Country:** USA **Primary Security ID:** 71722W107
Record Date: 03/26/2021 **Meeting Type:** Annual **Ticker:** PHAT
Primary CUSIP: 71722W107 **Primary ISIN:** US71722W1071 **Primary SEDOL:** BJLKVS6

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Phathom Pharmaceuticals, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--------------------------------------|-----------|----------|------------------|
| 1a | Elect Director Michael F. Cola | Mgmt | For | Withhold |
| 1b | Elect Director Asit Parikh | Mgmt | For | For |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Merck & Co., Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 05/25/2021 | Country: USA | Primary Security ID: 58933Y105 |
| Record Date: 03/26/2021 | Meeting Type: Annual | Ticker: MRK |
| Primary CUSIP: 58933Y105 | Primary ISIN: US58933Y1055 | Primary SEDOL: 2778844 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Leslie A. Brun | Mgmt | For | Against |
| 1b | Elect Director Mary Ellen Coe | Mgmt | For | For |
| 1c | Elect Director Pamela J. Craig | Mgmt | For | For |
| 1d | Elect Director Kenneth C. Frazier | Mgmt | For | For |
| 1e | Elect Director Thomas H. Glocer | Mgmt | For | For |
| 1f | Elect Director Risa J. Lavizzo-Mourey | Mgmt | For | For |
| 1g | Elect Director Stephen L. Mayo | Mgmt | For | For |
| 1h | Elect Director Paul B. Rothman | Mgmt | For | For |
| 1i | Elect Director Patricia F. Russo | Mgmt | For | Against |
| 1j | Elect Director Christine E. Seidman | Mgmt | For | For |
| 1k | Elect Director Inge G. Thulin | Mgmt | For | For |
| 1l | Elect Director Kathy J. Warden | Mgmt | For | For |
| 1m | Elect Director Peter C. Wendell | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |
| 4 | Provide Right to Act by Written Consent | SH | Against | Against |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Merck & Co., Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---------------------------------------|-----------|----------|------------------|
| 5 | Report on Access to COVID-19 Products | SH | Against | Against |

Corcept Therapeutics Incorporated

Meeting Date: 05/26/2021 **Country:** USA **Primary Security ID:** 218352102
Record Date: 04/16/2021 **Meeting Type:** Annual **Ticker:** CORT
Primary CUSIP: 218352102 **Primary ISIN:** US2183521028 **Primary SEDOL:** B00SCY1

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---------------------------------------|-----------|----------|------------------|
| 1.1 | Elect Director Gregg Alton | Mgmt | For | For |
| 1.2 | Elect Director G. Leonard Baker, Jr. | Mgmt | For | For |
| 1.3 | Elect Director Joseph K. Belanoff | Mgmt | For | For |
| 1.4 | Elect Director Gillian M. Cannon | Mgmt | For | For |
| 1.5 | Elect Director David L. Mahoney | Mgmt | For | For |
| 1.6 | Elect Director Kimberly Park | Mgmt | For | For |
| 1.7 | Elect Director Daniel N. Swisher, Jr. | Mgmt | For | For |
| 1.8 | Elect Director James N. Wilson | Mgmt | For | For |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Marinus Pharmaceuticals, Inc.

Meeting Date: 05/26/2021 **Country:** USA **Primary Security ID:** 56854Q200
Record Date: 03/30/2021 **Meeting Type:** Annual **Ticker:** MRNS
Primary CUSIP: 56854Q200 **Primary ISIN:** US56854Q2003 **Primary SEDOL:** BM8MVZ3

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|-------------------------------------|-----------|----------|------------------|
| 1.1 | Elect Director Charles Austin | Mgmt | For | For |
| 1.2 | Elect Director Michael R. Dougherty | Mgmt | For | For |
| 1.3 | Elect Director Elan Ezickson | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Marinus Pharmaceuticals, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | Against |

TherapeuticsMD, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 05/27/2021 | Country: USA | Primary Security ID: 88338N107 |
| Record Date: 04/05/2021 | Meeting Type: Annual | Ticker: TXMD |
| Primary CUSIP: 88338N107 | Primary ISIN: US88338N1072 | Primary SEDOL: B6WXT12 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Tommy G. Thompson | Mgmt | For | Withhold |
| 1.2 | Elect Director Robert G. Finizio | Mgmt | For | For |
| 1.3 | Elect Director Paul M. Bisaro | Mgmt | For | For |
| 1.4 | Elect Director J. Martin Carroll | Mgmt | For | For |
| 1.5 | Elect Director Cooper C. Collins | Mgmt | For | For |
| 1.6 | Elect Director Karen L. Ling | Mgmt | For | For |
| 1.7 | Elect Director Jules A. Musing | Mgmt | For | For |
| 1.8 | Elect Director Gail K. Naughton | Mgmt | For | For |
| 1.9 | Elect Director Angus C. Russell | Mgmt | For | Withhold |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Approve Non-Executive Stock Option Exchange Program | Mgmt | For | For |
| 4 | Amend Omnibus Stock Plan | Mgmt | For | For |
| 5 | Ratify Grant Thornton LLP as Auditors | Mgmt | For | For |

Zogenix, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 05/27/2021 | Country: USA | Primary Security ID: 98978L204 |
| Record Date: 03/29/2021 | Meeting Type: Annual | Ticker: ZGNX |
| Primary CUSIP: 98978L204 | Primary ISIN: US98978L2043 | Primary SEDOL: BYTJZL1 |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Zogenix, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director James B. Breitmeyer | Mgmt | For | Against |
| 1b | Elect Director Stephen J. Farr | Mgmt | For | For |
| 1c | Elect Director Mary E. Stutts | Mgmt | For | For |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Amend Omnibus Stock Plan | Mgmt | For | For |
| 5 | Increase Authorized Common Stock | Mgmt | For | For |

Aclaris Therapeutics, Inc.

Meeting Date: 06/03/2021 **Country:** USA **Primary Security ID:** 00461U105
Record Date: 04/05/2021 **Meeting Type:** Annual **Ticker:** ACRS
Primary CUSIP: 00461U105 **Primary ISIN:** US00461U1051 **Primary SEDOL:** BYV2W40

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Christopher Molineaux | Mgmt | For | For |
| 1.2 | Elect Director Bryan Reasons | Mgmt | For | For |
| 1.3 | Elect Director Vincent Milano | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Advisory Vote on Say on Pay Frequency | Mgmt | One Year | One Year |
| 4 | Ratify PricewaterhouseCoopers LLP as Auditor | Mgmt | For | For |

Cara Therapeutics, Inc.

Meeting Date: 06/03/2021 **Country:** USA **Primary Security ID:** 140755109
Record Date: 04/12/2021 **Meeting Type:** Annual **Ticker:** CARA
Primary CUSIP: 140755109 **Primary ISIN:** US1407551092 **Primary SEDOL:** BJ4YJ92

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Cara Therapeutics, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Harrison M. Bains, Jr. | Mgmt | For | For |
| 1.2 | Elect Director Susan Shiff | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Axsome Therapeutics, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 06/04/2021 | Country: USA | Primary Security ID: 05464T104 |
| Record Date: 04/12/2021 | Meeting Type: Annual | Ticker: AXSM |
| Primary CUSIP: 05464T104 | Primary ISIN: US05464T1043 | Primary SEDOL: BYZR4X4 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Herriot Tabuteau | Mgmt | For | For |
| 1.2 | Elect Director Mark Coleman | Mgmt | For | Withhold |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | Abstain |
| 4 | Advisory Vote on Say on Pay Frequency | Mgmt | One Year | One Year |

Amphastar Pharmaceuticals, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 06/07/2021 | Country: USA | Primary Security ID: 03209R103 |
| Record Date: 04/13/2021 | Meeting Type: Annual | Ticker: AMPH |
| Primary CUSIP: 03209R103 | Primary ISIN: US03209R1032 | Primary SEDOL: BNFWZS4 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--------------------------------|-----------|----------|------------------|
| 1a | Elect Director Mary Ziping Luo | Mgmt | For | Against |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Amphastar Pharmaceuticals, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1b | Elect Director Howard Lee | Mgmt | For | Against |
| 1c | Elect Director Michael A. Zasloff | Mgmt | For | For |
| 1d | Elect Director Gayle Deflin | Mgmt | For | For |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Arvinas, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 06/08/2021 | Country: USA | Primary Security ID: 04335A105 |
| Record Date: 04/12/2021 | Meeting Type: Annual | Ticker: ARVN |
| Primary CUSIP: 04335A105 | Primary ISIN: US04335A1051 | Primary SEDOL: BDZ30Q0 |

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Wendy Dixon | Mgmt | For | For |
| 1.2 | Elect Director Edward Kennedy, Jr. | Mgmt | For | For |
| 1.3 | Elect Director Bradley Margus | Mgmt | For | For |
| 1.4 | Elect Director Briggs Morrison | Mgmt | For | Withhold |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Advisory Vote on Say on Pay Frequency | Mgmt | One Year | One Year |
| 4 | Ratify Deloitte & Touche LLP as Auditors | Mgmt | For | For |

NGM Biopharmaceuticals, Inc.

| | | |
|---------------------------------|-----------------------------------|---------------------------------------|
| Meeting Date: 06/08/2021 | Country: USA | Primary Security ID: 62921N105 |
| Record Date: 04/16/2021 | Meeting Type: Annual | Ticker: NGM |
| Primary CUSIP: 62921N105 | Primary ISIN: US62921N1054 | Primary SEDOL: BJ1FD63 |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

NGM Biopharmaceuticals, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--------------------------------------|-----------|----------|------------------|
| 1a | Elect Director Jin-Long Chen | Mgmt | For | Withhold |
| 1b | Elect Director Roger M. Perlmutter | Mgmt | For | For |
| 2 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Pacira BioSciences, Inc.

Meeting Date: 06/08/2021 **Country:** USA **Primary Security ID:** 695127100
Record Date: 04/15/2021 **Meeting Type:** Annual **Ticker:** PCRX
Primary CUSIP: 695127100 **Primary ISIN:** US6951271005 **Primary SEDOL:** B3X26D8

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Laura Brege | Mgmt | For | For |
| 1.2 | Elect Director Mark I. Froimson | Mgmt | For | For |
| 1.3 | Elect Director Mark A. Kronenfeld | Mgmt | For | For |
| 2 | Ratify KPMG LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Amend Omnibus Stock Plan | Mgmt | For | For |

Endo International plc

Meeting Date: 06/10/2021 **Country:** Ireland **Primary Security ID:** G30401106
Record Date: 04/12/2021 **Meeting Type:** Annual **Ticker:** ENDP
Primary CUSIP: G30401106 **Primary ISIN:** IE00BJ3V9050 **Primary SEDOL:** BJ3V905

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---------------------------------|-----------|----------|------------------|
| 1a | Elect Director Mark G. Barberio | Mgmt | For | For |
| 1b | Elect Director Jennifer M. Chao | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Endo International plc

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1c | Elect Director Blaise Coleman | Mgmt | For | For |
| 1d | Elect Director Shane M. Cooke | Mgmt | For | Against |
| 1e | Elect Director Nancy J. Hutson | Mgmt | For | For |
| 1f | Elect Director Michael Hyatt | Mgmt | For | For |
| 1g | Elect Director William P. Montague | Mgmt | For | For |
| 1h | Elect Director M. Christine Smith | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | Against |
| 3 | Renew the Board's Authority to Issue Shares Under Irish Law | Mgmt | For | For |
| 4 | Renew the Board's Authority to Opt-Out of Statutory Pre-Emptions Rights Under Irish Law | Mgmt | For | For |
| 5 | Approve PricewaterhouseCoopers LLP as Auditors and Authorize Board to Fix Their Remuneration | Mgmt | For | For |

Nektar Therapeutics

Meeting Date: 06/10/2021 **Country:** USA **Primary Security ID:** 640268108
Record Date: 04/12/2021 **Meeting Type:** Annual **Ticker:** NKTR
Primary CUSIP: 640268108 **Primary ISIN:** US6402681083 **Primary SEDOL:** 2454445

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Jeff Ajer | Mgmt | For | For |
| 1b | Elect Director Robert B. Chess | Mgmt | For | For |
| 1c | Elect Director Roy A. Whitfield | Mgmt | For | For |
| 2 | Amend Omnibus Stock Plan | Mgmt | For | For |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 4 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | Against |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Reata Pharmaceuticals, Inc.

Meeting Date: 06/10/2021 **Country:** USA **Primary Security ID:** 75615P103
Record Date: 04/15/2021 **Meeting Type:** Annual **Ticker:** RETA
Primary CUSIP: 75615P103 **Primary ISIN:** US75615P1030 **Primary SEDOL:** BYY9FX8

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director William D. McClellan, Jr. | Mgmt | For | For |
| 1.2 | Elect Director William E. Rose | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | Against |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Omeros Corporation

Meeting Date: 06/11/2021 **Country:** USA **Primary Security ID:** 682143102
Record Date: 04/12/2021 **Meeting Type:** Annual **Ticker:** OMER
Primary CUSIP: 682143102 **Primary ISIN:** US6821431029 **Primary SEDOL:** B4NB858

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--------------------------------------|-----------|----------|------------------|
| 1a | Elect Director Thomas F. Bumol | Mgmt | For | Against |
| 1b | Elect Director Gregory A. Demopulos | Mgmt | For | For |
| 1c | Elect Director Leroy E. Hood | Mgmt | For | Against |
| 2 | Amend Omnibus Stock Plan | Mgmt | For | Against |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

DURECT Corporation

Meeting Date: 06/15/2021 **Country:** USA **Primary Security ID:** 266605104
Record Date: 04/20/2021 **Meeting Type:** Annual **Ticker:** DRRX
Primary CUSIP: 266605104 **Primary ISIN:** US2666051048 **Primary SEDOL:** 2640835

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

DURECT Corporation

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Mohammad Azab | Mgmt | For | For |
| 1.2 | Elect Director James E. Brown | Mgmt | For | For |
| 1.3 | Elect Director Gail M. Farfel | Mgmt | For | Withhold |
| 2 | Increase Authorized Common Stock | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |

Supernus Pharmaceuticals, Inc.

Meeting Date: 06/15/2021 **Country:** USA **Primary Security ID:** 868459108
Record Date: 04/16/2021 **Meeting Type:** Annual **Ticker:** SUPN
Primary CUSIP: 868459108 **Primary ISIN:** US8684591089 **Primary SEDOL:** B72ZBG4

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Georges Gemayel | Mgmt | For | For |
| 1.2 | Elect Director John M. Siebert | Mgmt | For | For |
| 2 | Ratify KPMG LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 4 | Approve Omnibus Stock Plan | Mgmt | For | For |

Aerie Pharmaceuticals, Inc.

Meeting Date: 06/17/2021 **Country:** USA **Primary Security ID:** 00771V108
Record Date: 04/19/2021 **Meeting Type:** Annual **Ticker:** AERI
Primary CUSIP: 00771V108 **Primary ISIN:** US00771V1089 **Primary SEDOL:** BFRTDG1

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Aerie Pharmaceuticals, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Mechiel (Michael) M. du Toit | Mgmt | For | For |
| 1.2 | Elect Director David W. Gryska | Mgmt | For | For |
| 2 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Atea Pharmaceuticals, Inc.

Meeting Date: 06/18/2021 **Country:** USA **Primary Security ID:** 04683R106
Record Date: 04/23/2021 **Meeting Type:** Annual **Ticker:** AVIR
Primary CUSIP: 04683R106 **Primary ISIN:** US04683R1068 **Primary SEDOL:** BLN9Z50

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---------------------------------------|-----------|----------|------------------|
| 1.1 | Elect Director Jean-Pierre Sommadossi | Mgmt | For | For |
| 1.2 | Elect Director Franklin Berger | Mgmt | For | Withhold |
| 2 | Ratify KPMG LLP as Auditors | Mgmt | For | For |

Ocular Therapeutix, Inc.

Meeting Date: 06/18/2021 **Country:** USA **Primary Security ID:** 67576A100
Record Date: 04/19/2021 **Meeting Type:** Annual **Ticker:** OCUL
Primary CUSIP: 67576A100 **Primary ISIN:** US67576A1007 **Primary SEDOL:** BNZB1X8

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Antony Mattessich | Mgmt | For | For |
| 1.2 | Elect Director Charles Warden | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Ocular Therapeutix, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 3 | Approve Omnibus Stock Plan | Mgmt | For | Against |
| 4 | Increase Authorized Common Stock | Mgmt | For | For |
| 5 | Ratify PricewaterhouseCoopers LLP as Auditors | Mgmt | For | For |

Intra-Cellular Therapies, Inc.

Meeting Date: 06/21/2021 **Country:** USA **Primary Security ID:** 46116X101
Record Date: 04/28/2021 **Meeting Type:** Annual **Ticker:** ITCI

Primary CUSIP: 46116X101 **Primary ISIN:** US46116X1019 **Primary SEDOL:** BHC80P4

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.1 | Elect Director Michael Rawlins | Mgmt | For | For |
| 1.2 | Elect Director Joel S. Marcus | Mgmt | For | Withhold |
| 2 | Increase Authorized Common Stock | Mgmt | For | For |
| 3 | Ratify Ernst & Young LLP as Auditors | Mgmt | For | For |
| 4 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Odonate Therapeutics, Inc.

Meeting Date: 06/24/2021 **Country:** USA **Primary Security ID:** 676079106
Record Date: 05/07/2021 **Meeting Type:** Annual **Ticker:** ODT

Primary CUSIP: 676079106 **Primary ISIN:** US6760791060 **Primary SEDOL:** BD1KGM3

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|------------------------------|-----------|----------|------------------|
| 1.1 | Elect Director Kevin Tang | Mgmt | For | For |
| 1.2 | Elect Director Aaron Davis | Mgmt | For | Against |
| 1.3 | Elect Director Craig Johnson | Mgmt | For | Against |
| 1.4 | Elect Director Laura Johnson | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021
Location(s): State Street Global Advisors
Institution Account(s): SPDR S&P Pharmaceuticals ETF

Odonate Therapeutics, Inc.

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1.5 | Elect Director Robert Rosen | Mgmt | For | For |
| 2 | Ratify Baker Tilly US, LLP as Auditors | Mgmt | For | For |
| 3 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |

Royalty Pharma Plc

Meeting Date: 06/24/2021 **Country:** United Kingdom **Primary Security ID:** G7709Q104
Record Date: 06/22/2021 **Meeting Type:** Annual **Ticker:** RPRX

Primary CUSIP: G7709Q104 **Primary ISIN:** GB00BMVP7Y09 **Primary SEDOL:** BMVP7Y0

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|--|-----------|----------|------------------|
| 1a | Elect Director Pablo Legorreta | Mgmt | For | For |
| 1b | Elect Director Henry Fernandez | Mgmt | For | For |
| 1c | Elect Director Bonnie Bassler | Mgmt | For | For |
| 1d | Elect Director Errol De Souza | Mgmt | For | Against |
| 1e | Elect Director Catherine Engelbert | Mgmt | For | For |
| 1f | Elect Director William Ford | Mgmt | For | For |
| 1g | Elect Director M. Germano Giuliani | Mgmt | For | For |
| 1h | Elect Director Ted Love | Mgmt | For | Against |
| 1i | Elect Director Gregory Norden | Mgmt | For | Against |
| 1j | Elect Director Rory Riggs | Mgmt | For | For |
| 2 | Advisory Vote to Ratify Named Executive Officers' Compensation | Mgmt | For | For |
| 3 | Advisory Vote on Say on Pay Frequency | Mgmt | One Year | One Year |
| 4 | Ratify Ernst & Young as Auditors | Mgmt | For | For |
| 5 | Accept Financial Statements and Statutory Reports | Mgmt | For | For |
| 6 | Approve Remuneration Policy | Mgmt | For | For |
| 7 | Approve Remuneration Report | Mgmt | For | For |
| 8 | Ratify Ernst & Young as U.K. Statutory Auditors | Mgmt | For | For |

Vote Summary Report

Reporting Period: 07/01/2020 to 06/30/2021

Location(s): State Street Global Advisors

Institution Account(s): SPDR S&P Pharmaceuticals ETF

Royalty Pharma Plc

| Proposal Number | Proposal Text | Proponent | Mgmt Rec | Vote Instruction |
|-----------------|---|-----------|----------|------------------|
| 9 | Authorise Board to Fix Remuneration of Auditors | Mgmt | For | For |